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Background – Traditional Medicines (TM) are often used by people living with HIV/AIDS (PLWA) 
alone or in combination with antiretroviral therapy (ART) to combat illnesses associated with HIV or 
the side effects of ART. Very few studies on clinical subjects have been carried out to find out the 
effects of co-administration of TM with ART 
Aim 
To investigate the effects of concurrent use of prescribed antiretroviral medicines (ARVs) and African 
Traditional medicines (ATM) on the CD4+ lymphocyte Count and Viral Load (VL) of PLWA in the 
eThekwini Metropolitan area. 
Method:   
A descriptive and exploratory study was carried out in two phases at four health facilities offering ART 
in the eThekwini metro. Phase 1 was a cross sectional descriptive study aimed at collecting information 
on patient demographics and ATM use. Phase 2 of the study was a longitudinal study which involved 
collection of data from the patient’s charts using a case report form. The data was collected 
retrospectively and prospectively in phase 2.  
Results:   
281 patients met the inclusion criteria, gave consent to participate in the study and had usable 
information in their patient files. The majority of the participants were females (194/281, 69.9%) and 
almost all (272/281, 96.8%) were of African ethnicity and resided in a local township (64.4%). Fourteen 
out of the 281 (14/281 4.98%) patients reported concurrent use of ATM with ARVs during the study 
period. The most commonly used ATM was the African potato (9/14, 64.3%) followed by Sutherlandia 
(5/14, 21.4%), StamettaTM and uBhejani.  The differences between the two means in the cohort taking 
ARV alone (–ATM) and the cohort which used ATM and ARVs concurrently (+ATM) at each CD4+ 
cell count measure were not significant at 5% level for Time 0 (p=0.18), Time 2 (p=0.26) and Time 3 
(p=0.09). The differences between the two means in the –ATM and +ATM groups were significant at 
5% level for Time 0 (p=0.013), marginally significant at Time 1 (p=0.048), significant at Time 2 







Concurrent ARV and ATM use is quite low (4.98%) and this may indicate efficient pre-counselling 
efforts by healthcare professionals before ARV initiation. This study shows that there are no 
significant differences in CD4+ and inconclusive effects on VL, between patients taking both ARV 




















1.1 BACKGROUND AND RATIONALE FOR THE STUDY  
It is estimated that there are approximately 200,000 African traditional healers in South Africa and that 
between 70 and 80 per cent of South Africans use the services of Traditional Health Practitioners (THP) 
[1]. South Africa like many developing countries has a pluralistic healthcare system wherein a 
modernised first world medical system co-exists with a variety of non-conventional health care systems 
such as local indigenous systems founded on traditional beliefs and practices [2]. 
Human immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) has 
grown to pandemic proportions and has become a major health problem worldwide. South Africa has 
an estimated 6.8 million people living with HIV and this represents the largest number of people living 
with HIV (PLWA) in any country [3]. PLWA often use a wide range of traditional medicine (TM) 
products together with their prescribed antiretroviral medicines (ARVs) in the treatment of HIV/AIDS 
related illnesses [4]. 
Although the use of TM is widespread, their use is not well researched, and consequently poorly 
regulated [5]. Limited clinical trials of efficacy exist, and low-level evidence of harm may indicate the 
potential for drug interactions with many medicines including the commonly used ARVs [5]. 
1.2 LITERATURE REVIEW 
1.2.1 Epidemiology of TM use 
The World Health Organisation (WHO) in its 2014-2023 strategy for Traditional medicines (TM) 
acknowledges that THP are either the mainstay of primary health care or a significant complement to 
health care delivery in most developing countries in the world, although their role in the health care 
system is usually understated [6].  
1.2.2 HIV/AIDS and Antiretroviral Therapy (ART)  
HIV/AIDS has grown to pandemic proportions and has become a major health problem worldwide. 
South Africa has an estimated 6.8 million people living with HIV and this represents the largest number 
of people living with HIV in any country in the world [3].   
To date, Antiretroviral therapy (ART) using antiretroviral drugs (ARV) is the only proven management 
of HIV infection, making their effective distribution and uptake an essential component of any 




scale roll-out of the antiretroviral therapy programme [7]. By mid-2011, approximately 1.9 million 
people were estimated to have been enrolled in this programme [8]. In 2013, the guidelines for ARV 
treatment in South Africa were revised to recommend the fixed-dose regimen (FDC) which consists of 
tenofovir (TDF), emtricibatine (FTC) and efavirenz (EFV) as the first line treatment in order to improve 
adherence and retention [8]. The World Health Organisation (WHO) has also since reviewed its 
guidelines, and now recommends that ART should be initiated in all adults living with HIV at any CD4+ 
cell count {9].   
1.2.3 Medical Pluralism in the era of HIV/AIDS  
Medical pluralism is the co-existence and use of more than one healthcare system for diagnosing and 
treating diseases [10].  A study in 2008 revealed that 4.1% of 618 PLWA interviewed at three hospitals 
in KwaZulu Natal (KZN) believed that they could cure HIV through the use of TM only [11]. This same 
study on treatment naive PLWA also found African Traditional Medicine (ATM) had been used for 
HIV in the past six months by 51.3% [11]. 
 
In Uganda, a 2007 study showed that 63.5 % of PLWA had used ATM after HIV diagnosis and same-
day concomitant ATM and ARV use was reported by 32.8% of the patients surveyed [12]. In a tertiary 
hospital in Kano, Northwest Nigeria, it was found that 4.25% of the 430 patients surveyed used ARV 
and traditional medicine concomitantly [13].  A study of 67 PLWA done at three ART centres in the 
Kumasi Metropolis in Ghana found that concomitant ATM and ARV use was reported by 53.2% of the 
patients [14]. An astounding 98.2% of 388 patients interviewed at the Family Care Centre (FCC) ART 
clinic in Harare, Zimbabwe, were found to be using at least one ATM concurrently with their ARV 
medication [15]. A 2012 cross-sectional study which involved 100 participants enrolled at ARV clinics 
in two South African provinces showed that 79% of PLWA had used ATM prior to a diagnosis of HIV 
[16].   According to a 2007 study by Malangu, 7.7% of PLWA patients on ART in Pretoria, South Africa, 
concurrently used traditional health care, based on a self-reported survey on use of TCAM and over-
the-counter medicines by HIV patients [17]. Despite the widespread use of TM in HIV/AIDS, a 2009 
Cochrane review of Herbal medicines for treating HIV infection and AIDS found insufficient evidence 
to support the use of herbal medicines in PLWA and that the potential for any benefits needed to be 
studied further [18].  
1.2.4 Antiretroviral Therapy and Drug-Herb Interactions  
Typically, drug-drug interactions (DDI) and Herb-Drug interactions (HDI) may occur in at any of the 
stages of Absorption, Distribution, Metabolism and Excretion (ADME) phases of the pharmaceutical 




Studies have shown that most ARV are metabolised via the cytochrome P450 3A4 enzyme system 
(CYP3A4) and the P-glycoprotein systems [19]. Herb-induced inhibition or induction of the cytochrome 
enzymes can alter the metabolism of ARVs, leading to adverse effects or lack of efficacy or drug 
toxicity [19].  A 2013 study for example, showed that Sutherlandia may inhibit clearance of drugs 
metabolised by the CYP450 pathway and has potential to interact with medicines which are metabolised 
by the same pathway [20]. Sutherlandia has also been shown to have an adverse effect on the absorption 
and metabolism of Atazanavir in the clinical setting [21]. 
Mills et al. in 2005 showed that extracts of African potato (Hypoxis hemerocallidea) had significant 
effects on cytochrome P450 3A4 in-vitro metabolism and potentially could result in sub-therapeutic 
plasma concentrations [22].  
The above studies on TM and ARV use were affirmed by a 2014 laboratory study of the inhibition of 
major drug metabolising enzymes by Hypoxis hemerocallidea (H. hemerocallidea), Echinacea 
purpurea (E. purpurea), Moringa oleifera (M. oleifera), Taraxacum officinale (T. officinale) and 
Lessertia frutescens (L. frutescens) which demonstrated that TM have the potential to interact with 
ARV [23].  A 2013 study on adult volunteers, by Gwaza et al. showed that hypoxis when taken 
concurrently with the ARV drug Lopinavir/Ritonavir (LPV/r) is well-tolerated and is not associated 
with clinically significant changes in LPV/r pharmacokinetics [24].   
1.3 PROBLEM STATEMENT AND CLINICAL SIGNIFICANCE OF THE STUDY 
Due to the widespread use of traditional medicines, the high prevalence of HIV/AIDS, and the use of 
ARVs in HIV infected patients it was pertinent to investigate the effects of concurrent use of ARVs and 
Traditional medicines on the CD4 count and Viral Load in PLWA. These parameters are good clinical 
indicators for the patient’s health outcomes {9]. 
This study is significant because it attempts to address some gaps in the current research pertaining to 
ARV and ATM use in PLWA; Updated data on prevalence of ATM use amongst PLWA is outdated 
with most available data on trends of ATM use amongst PLWA for the period before the advent of the 
ARV roll-out programme. In addition, studies concerning concurrent ARV and ATM use and the 
potential Drug Herb- interactions (DHI), are mostly in-vitro studies [24]. Studies on human subjects are 
limited and the data is scanty. 
Furthermore, covariates and patient characteristics which may influence the treatment outcomes in 




1.4 AIM OF THE STUDY 
To investigate the effects of concurrent use of prescribed antiretroviral medicines (ARVs) and African 
Traditional medicines (ATM) on the CD4+ lymphocyte Count and Viral Load (VL) of PLWA in the 
eThekwini Metropolitan area of KwaZulu- Natal 
1.5 OBJECTIVES OF THE STUDY 
The objectives of the study were as follows:  
 To determine the prevalence of concurrent African Traditional medicine and ARV use. 
 To identify the most commonly used African Traditional medicines in the management of HIV 
which are used concurrently with ARV in KZN. 
 To document the CD4 and VL of patients taking concurrent African Traditional medicine and 
ARV over a 9-month period. 
 To determine the presence of Opportunistic Infections (OI) in patients taking both ARV and 
African TM if taking ATM results in a negative effect on CD4 and VL. 
 To disseminate the findings into the public domain through a recognised and peer reviewed 
scientific journal. 
1.6 METHODOLOGY 
1.6.1 Study design 
The study was conducted at four public ART clinics in the eThekwini metro in the period October 2014 
to November 2015. The clinics were randomly selected from a list supplied by the provincial department 
of health of facilities that supply ARV treatment in the metro. 
1.6.2 Sample size and Selection 
Based on the figures outlined in the 2011 operational plan for the comprehensive HIV and AIDS care, 
management and treatment, a total of 12000 patients was postulated to attend the ART Clinics in the 
four health facilities in the study period [7]. An alpha error level of 0.1, beta 0.5, was desired for this 
study and this required a minimum sample size of 265 at ±10% precision level [25].  A sample size of 




in order to cater for any ‘loss to follow up’ patients. Based on the patient responses, the patients were 
allocated into two groups;  
1) The Control group (-ARV) which consisted of patients undergoing ARV treatment but who do 
not use traditional medicines concurrently.  
2) The second group also referred to as the treatment group (+ARV) which consisted of patients 
who used ARV concurrently with ATM. 
Inclusion criteria   
The following Inclusion criteria were used for this study; 
1) HIV infected patients. 
2) Patients must have been stabilised on the same ARV regimen for the past 6 months 
3) Patients must be on the same fixed dose ARV regimen. 
Exclusion criteria   
The following Exclusion criteria will apply; 
1) Patients under the age of 18 years. 
2) Patient using concomitant chronic western medicine (excluding ARVs). 
3) Patients who use other alternative therapies (excluding ATMs) 
1.6.3 Data collection technique and instruments 
Data was collected by the researcher retrospectively and prospectively over a period of twelve months 
in two phases; 
Phase 1: During phase 1 of the study, data was collected using an anonymous coded questionnaire 
(Appendix 1) after consent was given by the patients. The code on the questionnaire was written next 
to the respective spread sheet data. This information was necessary for phase 2 selection of participants.  
The structured data extraction form consisting of close-ended questions was used to collect data during 
interviews with participants. Questionnaires were available in English as well as Zulu and recorded the 
following criteria; 
1. Patient Characteristics (Age, Gender, Ethnicity, Level of Education). 
2. Current ARV Regimen. 




4. Current TM used. 
5. Duration of TM Use. 
6. Reason for TM Use. 
Thereafter exclusion of participants took place based on the exclusion criteria. 
Phase 2: Phase two of the study was a longitudinal study (Retrospective, 6 months and prospective 12 
months). Patient charts were coded with a unique number to match the questionnaire number.  Clinical 
data obtained from the patient files included; 
1. Previous and Current ART Regimen(s). 
2. Opportunistic Infections. 
3. Patient viral load and CD4+ Lymphocyte Count and weight. 
 
The information obtained was recorded on a Case Report form for each patient (Appendix 2). 
Prospective data collection was done every 6 months and consisted of serial measurements of the above 
mentioned clinical variables over a twelve-month period. Prospective data collection was done using 
patients’ medical chart history. No further contact was made with the patient phase 2 of this study and 
so no information on continued TM use could be ascertained.  Information collected consisted only of 
clinical data recorded in the patient medical chart. This was then recorded on the same Case Report 
form (Appendix 2).   
1.6.4 Pilot Study 
A pilot study for Phase 1 of the study was conducted on thirty patients prior to the actual data collection 
period. This was done in order to review the data collection instruments and assess their suitability for 
use in the study. This was also done to increase the validity and reliability of the data collection 
instruments and to ensure content validity for the study. Another aim of the pilot study was to check the 
feasibility of the study and also amend the questions in the data management tools where necessary. 
Data from the pilot study was not included in the final analysis. 
1.6.5 Ethical considerations 
Ethical clearance for the study was obtained from University of KwaZulu-Natal Biomedical Research 




HRKM240/14) in the provincial Department of Health as well as permission from the Chief Executive 
Officer’s (CEO) of the four health facilities. 
Furthermore, written informed consent was obtained from each patient after details of the study, 
including the aims, risks and benefits of the study, were clearly explained to the patients in a language 
that the patient was comfortable with. The patient information and consent forms were made available 
in English, and isiZulu.  In addition, the patients were also provided with the telephone number of one 
of the clinics doctors to answer any questions as well as the UKZN BREC to verify the authenticity of 
the study. To protect patient confidentiality, especially the patients’ HIV status, a unique study number 
was assigned to each patient and reporting on patient’s information was done anonymously. Patients 
taking part in the study did not receive any direct feedback on their CD4+ levels or any other clinical 
information unless it was indicative of non-compliance to ARV or treatment failure in which case the 
responsible clinician was contacted. The study was conducted according to internationally accepted 
ethical standards and guidelines and all patients were treated according to the regular standard of care 
without any prejudice or favour. 
Participants were informed that they had the right to withdraw from the study at any time if they chose 
to do so without providing any reason. 
1.6.6 Data analysis 
Data analysis for this study was both quantitative as well as descriptive. Statistical Package for the 
Social Sciences Package for Windows® by IBM (IBM SPSS®), Version 21, was utilised for data 
analysis. All entered data was cross checked/proof read by a second person and corrections were made 
if necessary. 
Results were expressed in terms of frequency, mean values, standard deviations (SD). Frequencies and 
proportions (%) were calculated to describe categorical variables such as Age, Gender, place of 
residence, level of education and ATM use. To allow for sorting and counting of responses, categories 
were developed and responses were sorted and tabulated according to labelled categories. 
In the event of the patient charts having missing clinical information (CD4+ and VL measurements), 
the average CD4+ and/or VL for the available readings was used in the place of the missing data. 
Average CD4+ and VL for both cohorts at Time 0 (6 months retrospective), Time 1 (Baseline), Time 2 
(6 months prospective) and Time 3 (12 months prospective) were determined. The association between 
the Health outcomes (CD4+ counts and Viral Loads) and use of ATM were examined using a standard 




1.7 OUTLINE OF THE DISSERTATION 
The chapters in this dissertation are presented as follows: 
Firstly, in Chapter 1, the introduction, background, rationale for the study as well as the literature 
review for the study are presented. In this chapter, a Socio-epidemiology of TM use in South Africa is 
given. The phenomenon of medical pluralism is explained as well as the role of the THP in the 
management of HIV/AIDS as recorded in current literature. Furthermore, the recommended ARV 
treatment guidelines are outlined and the pharmacokinetics of some ARV drugs as well as commonly 
used ATM for the management of HIV/AIDS are also reviewed.  Literature on in-vitro studies of the 
pharmacokinetic profiles of some commonly used ATM are cited including Herb-Drug Interactions 
with antiretroviral medicines. The significance of the study, research questions as well as aims and 
objectives of the study are also defined. The Chapter concludes by outlining the methodology used in 
the study including the study design, site, sample selection, data collection instruments and ethical 
considerations for the two phases of the study.  
Chapter 2 is a manuscript derived from this study and reports on the main objective of this study. The 
manuscript title is, “Effects of concurrent Antiretroviral and African traditional medicines on the CD4 
Count and Viral load profiles of People living with HIV/AIDS (PLWA) in the eThekwini Metropolitan 
area” presented according to South African Medical Journal author guidelines. The manuscript presents 
the data and results of this study. 
Chapter 3 offers the synthesis of the study including a discussion on key findings, conclusions drawn 
from the research, outlines the limitations of this study and makes recommendations based on the 
findings of this research.
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Background: People living with HIV/AIDS (PLWA) often use African Traditional Medicines 
(ATM) either alone or in combination with western medicines including Antiretrovirals 
(ARV).  
Objective: To explore the prevalence of concurrent Antiretrovirals (ARV) and African 
Traditional medicines (ATM) use and determine the effects of any concurrent use on the CD4+ 
Lymphocyte Count and Viral Load (VL) of PLWA in the eThekwini Metropolitan area. 
Methods: A descriptive and exploratory study was carried out on 360 patients. Information 
was gathered on patient’s socio-economic characteristics, ATM usage, outcome measures of 
HIV disease progression (CD4+ Count, VL). The data was analysed using descriptive statistics, 
univariate and multivariate analyses.  
Results: 4.98% (14/281) of the patients used ATM and ARV concurrently during the study 
period. Over 65% (185/281) reported ATM use before diagnosis with HIV whilst 77.6% 
(218/281) reported previous ATM use after their HIV diagnosis but before initiation with ARV. 
Place of residence (p=0.004), age (p<0.001) and education level (P=0.041) were found to be 
significantly and positively correlated with ATM use. There were no statistically significant 
changes in mean plasma CD4+ Count and inconclusive effects on VL during the period of the 
study in the group taking ARV alone when compared with the group using ARV and ATM 
concomitantly.  
Conclusion:  Concurrent ARV and ATM use is quite low (4.98%) when compared to ATM 
use before HIV diagnosis and after HIV diagnosis but before initiation with ARV. This may 
point to efficient pre-counselling efforts before ARV initiation by healthcare professionals. 
This study also demonstrated that there were no significant differences in the CD4+ and 
inconclusive effects on VL, between patients taking both ARV and ATM concomitantly and 
those using ARV alone. 
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Human immunodeficiency Virus and Acquired Immune Deficiency Syndrome (HIV/AIDS) has grown 
to pandemic proportions and has become a major health problem worldwide. Approximately 36.9 
million people worldwide are living with HIV and since 2000 around 25.3 million people have died as 
a result of AIDS related illnesses [1].  According to the 2014 Joint United Nations Programme on HIV 
and AIDS (UNAIDS) update, sixty-nine percent of people infected with the HIV live in Sub-Saharan 
Africa [1]. South Africa has an estimated 6.8 million people living with HIV and this represents the 
largest number of people living with HIV in any [1]. HIV/AIDS has worsened the demands on the health 
care system in Africa and has put an already overburdened system under further strain [1]. Antiretroviral 
therapy (ART) using antiretroviral drugs(ARV) is the only proven management of HIV-infection and 
have led to reduction in HIV related opportunistic infections and AIDS related deaths, and have thus 
improved substantially the quality of life in People living with HIV/AIDS (PLWA) [2].  
It is estimated that there are approximately 200000 African traditional healers in South Africa and that 
between 70 and 80 per cent of South Africans use the services of Traditional Health Practitioners (THP) 
[3].  South Africa like many developing countries has a pluralistic healthcare system wherein a 
modernised first world medical system co-exists with a variety of non-conventional health care systems 
such as local indigenous systems founded on traditional beliefs and practices [4]. 
In South Africa, the use of modern medicines has never fully replaced the indigenous system, and THPs 
continue to be consulted by the black population including PLWA for a variety of reasons [3]. The 
commonly treated illnesses including nausea and vomiting, lack of energy, lack of appetite, skin 
disorders, weight loss and diarrhea. Traditional Medicine (TM) are also used to treat the side effects of 
ARV drugs as well as fungal infections, dizziness, stomach upsets and pain [5]. Other reasons for TM 
use in PLWA is to supplement dietary intake, boost energy levels and improve immune response as 
well as a misguided belief that some TM can cure HIV/AIDS [6]. African traditional medicines (ATM) 
are regarded as a credible and convenient source of health care and dual treatment regularly takes place 
as a result [4]. THP thus have a crucial role to play in building the health system of South Africa including 
the management of PLWA [5].  
During the peak of the HIV/AIDS pandemic in the late 1990’s before the era of massive ARV roll-out 
programs, when ARVs were largely unaffordable and inaccessible, ATM were the mainstay of HIV 
management amongst PLWA in Africa [5]. The advent of ARV rollout programs did not substitute ATM 
use amongst the population [3] and many studies attest to this. In Uganda for example, a 2007 study 
showed that 63.5 % of PLWA had used TM after HIV diagnosis and same-day, concomitant ATM and 
ARV use was reported by 32.8% of the patients surveyed [7]. In a tertiary hospital in Kano, Northwest 
Nigeria, it was found that 4.25% of the 430 patients surveyed used ARV and traditional medicine 
concomitantly [8].  A survey of 67 PLWA done at three ART centres in the Kumasi Metropolis in Ghana 
found that concomitant TM and ARV use was reported by 53.2% of the patients [9]. An astounding 
98.2% of 388 patients interviewed at the Family Care Centre (FCC) ART clinic in Harare, Zimbabwe 
were found to be using at least one ATM concurrently with their ARV medication [10]. 
A cross-sectional survey done in 2007 among PLWA attending a workplace ART clinic in South Africa 
found that 23% used ATM concurrently with their ATM [6]. A 2012 cross-sectional study which 
involved 100 participants enrolled at ARV clinics in two South African provinces showed that less than 
20% of participants used TM and ARV simultaneously [11]. However, close to 80% of participants 
utilised TM before contracting HIV, which is in keeping with approximate estimates by the WHO [12]. 
According to Malangu, 7.7% PLWA on ART in Pretoria, South Africa, concurrently used traditional 
health, care and over-the-counter medicines. [13]. 
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Although the use of Traditional Medicines (TM) is widespread, their use is not well researched, and 
consequently poorly regulated [4]. Limited meta-analyses of safety and efficacy exist and low-level 
evidence of harm identifies the potential for herb-drug interactions (HDI) with many medicines 
including the commonly used ARV [14]. 
The potential HDI may occur in similar fashion to the typical Drug-Drug interactions (DDI) at any of 
the stages of Absorption, Distribution, Metabolism and Excretion (ADME) phases of the 
pharmaceutical disposition of the drug in the human body affecting the entire pharmacokinetic profile 
of the drug [15]. Herb-induced inhibition or induction of the cytochrome enzymes can alter the 
metabolism of ARVs, leading to adverse effects or lack of efficacy [15]. The concomitant intake of TM 
in patients using ARVs may result in lowering of plasma drug concentrations resulting in treatment 
failure, drug resistance and possibly death of the patient [15]. Alternatively, concomitant intake may also 
result in increased plasma drug concentrations resulting in drug toxicity [15]. 
Mills et al. in 2005 showed that extracts of African potato (Hypoxis hemerocallidea) had significant 
effects on cytochrome P450 3A4 in-vitro metabolism and so potentially could result in sub-therapeutic 
plasma concentrations [16]. A 2014 laboratory study of the inhibition of major drug metabolising 
enzymes by Hypoxis hemerocallidea (H. hypoxis), Echinacea purpurea (E. purpurea), Moringa 
oleifera (M. oleifera) Taraxacum officinale (T. officinale) and Lessertia frutescens (L. frutescens) 
which demonstrated that TM have the potential to interact with ARV [17]. Conversely, a 2013 study on 
adult volunteers, by Gwaza et al. showed that Hypoxis when taken concurrently with 
lopinavir/ritonavir(LPV/r) is well-tolerated and is not associated with clinically significant changes in 
LPV/r pharmacokinetics [18].  International guidelines for the management of HIV/AIDS recommend 
the use of plasma viral load (VL) measurements as the key tool in predicting HIV viral suppression and 
treatment success for patients on ART [19]. In resource limited settings which have inadequate access 
for VL measurements, treatment outcomes in PLWA on ART are measured using other clinical tools 
such as CD4+ T-cell (CD4) count, changes in the patient’s Body Mass Index (BMI) as well as the 
presence or absence of opportunistic diseases [20]. Notwithstanding the laboratory studies mentioned 
above and others, and the known, albeit usually sub-clinical DDI in the components of most ART 
regimens, there remains no definitive position by most policy makers on the effect of individual ATM 
on the effects of concurrent use of ART and ATM on VL and CD4+ counts amongst PLWA due to the 
absence of a large randomised control trials 
 Aim and Objectives: 
The objective of the study was to explore the occurrence of concurrent ART and ATM use amongst 
PLWA in the eThekwini Metropolitan area with the following aims: to determine the Socio-
demographic profiles of the respondents, the types of ATM used and the reasons for their use of ATM 
with ARV as well as to determine the effects of any concurrent use on the CD4+ Lymphocyte Count 
and Viral Load (VL) of such patients.  
 
Ethical considerations 
Ethical clearance for the study was obtained from University of KwaZulu-Natal Biomedical Research 
Ethics Committee (BREC REF: BE272/14), the KwaZulu-Natal health Research Committee (REF: 
HRKM240/14) in the provincial Department of Health as well as permission from the CEO’s of the 
four health institutions before data collection commenced. 
 
 




Design, Setting and Study population  
The study was conducted in two phases. The first phase was a cross sectional descriptive study aimed 
at collecting information on patient demographics and ATM use as well as to recruit participants for 
the second phase of the study. The second phase was a longitudinal study which involved data collection 
from the patient’s charts using a Case Report Form. The study was carried out in the region of the 
eThekwini metropolitan area. The eThekwini metro is a mostly urban area consisting of approximately 
3.5 million people and is located in the east coast of the Republic of South Africa (RSA) [21]. The 
population is comprised mostly of black African (73.8%), followed by Indian/Asian (16.7%), White 
(6.6%) and coloureds (2.5%) [21]. The population is serviced with sixteen provincial hospitals and eight 
community health centres [22].  The study was conducted at four public health facilities that supply ARV 
treatment in the eThekwini Metropolitan (Metro) area. These facilities were randomly selected from a 
list supplied by the provincial department of health of facilities that supply ARV treatment in the metro. 
A minimum sample size of 360 HIV-infected, treatment experienced adults (≥18 years old) was 
determined to be a suitable number in order to cater for any ‘loss to follow up’ patients. Every second 
patient attended to at the health facility was approached with the study information leaflet to participate 
in the study. After obtaining their consent patients were recruited continuously until the desired sample 
size of 360 participants who met the inclusion criteria was achieved. Only patients who had been 
stabilised on the same Fixed Dose first-line ART regimen which consists of tenofovir (TDF), 
emtricibatine (FTC) and efavirenz (EFV) for the past 6 months were considered for the study. Patients 
of the FDC were preferred by the researcher as this is the most commonly used first line regimen 
according to current treatment guidelines [23]. Furthermore, patients on the FDC were deemed to be more 
likely to be compliant to treatment and so negate non-adherence as a confounder to treatment failure 
[23].  
 Instrument, Data Collection, Capture and Analysis 
An anonymous coded questionnaire was administered to each of the selected 360 participants The 
variables gathered included characteristics such as age, gender, ethnicity, level of education and place 
of residence., Other variables collected were current ARV regimen, previous and current ATM use, 
names and routes of administration of ATM used, reason for ATM use and awareness of any dangers 
in concurrent ATM and ARV use. Based on responses from this phase, patients were divided into two 
cohorts; users of ARV alone (-ATM) or users of both ARV and ATM (+ATM). 
Subsequent to the collection of the above mentioned patient data, a second phase of the study was 
initiated. This was a longitudinal study which involved data collection of patient clinical information 
from the patient’s charts using a Case Report Form (CRF). The data was collected both retrospectively 
(6 months) and prospectively (over 12 months, in six month intervals). Clinical data collected included 
CD4+ lymphocyte counts, patient Viral load (VL), treatment failure, presence of Adverse Drug 
Reactions (ADR) and Opportunistic infections (OI) as well as any documented ATM use if available. 
The data was then captured and analysed using Statistical Package for the Social Sciences Package for 
Windows® by IBM (IBM SPSS®) version 21. Results were expressed in terms of frequency, mean 
values and Standard Deviations (SD). Frequencies and proportions (%) were calculated to describe 
categorical variables such as Age, Gender, place of residence, level of education and ATM use. Results 
from open ended questions were captured using IBM SPSS ®. Categories were developed and responses 
were sorted and tabulated according to labelled categories to allow for sorting and counting of 
responses.  
Average CD4+ and VL for both cohorts at Time 0 (6 months retrospective), Time 1 (Baseline), Time 2 
(6 months prospective) and Time 3 (12 months prospective) were determined. In the event of the patient 
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charts having missing clinical information (one or more missing CD4+ and/or VL measurements), the 
average of the available readings would be used in the place of the missing data. The association 
between the Health outcomes (Average CD4+ counts and Viral Loads) and use of ATM were examined 




Out of the subset of 360 patients who met the inclusion criteria and so chosen to participate in this study, 
79 patients were excluded due to ‘loss to follow-up’ either through death (4 patients) or through 
completely unusable clinical information in the patient charts (absent CD4+ or VL).  
Socio-Demographic characteristics 
Out of the remaining 281 patients surveyed, 69.9% were females and almost all (96.8%) were of African 
(black) ethnicity. The mean age of the participants was 39 (with a range from 19 to 69 years). The 
majority of the participants were relatively under-educated with only 6.7% having obtained a tertiary 
qualification and most (48.4) only having a primary education. It was also found that the majority of 
the patients (64.4%) resided in an urban township. 
The sample characteristics are depicted in figure 1; 
. 
 
Figure 1:  Sample Size Population Characteristics 
 
 
360 patients who met the inclusion criteria and 
gave consent to participate in the study were 
considered.
79 patients were excluded 
due to ‘loss to follow-up’
75 patients ‘lost to follow-
up’ had incomplete clinical 
information in the patient 
files. With either No Viral 
Load or No CD4+ 
measurement during the 
period of study
4 patients ‘lost to follow-up’ 
sadly passed away
281 patients met the 
inclusion criteria, gave 
consent to participate in the 
study and had usable 
information in their patient 
files.
267 patients used ART 
alone (-ATM)
14 patients used ATM and 
ART concurrently (+ATM)
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Demographics and ATM use 
The majority (71.4%) of concurrent ATM and ARV (+ATM) users were Africans (black) above the 
age of 40 and resided in urban townships (57.1%). Most of the patients (85.7%) who took ATM 
concurrently with ARV had primary education or lower qualification. Sixty-three (22.4%) patients 
reported to never have used ATM. 
Table 1 shows the summary of the demographic characteristics of patients surveyed, stratified by ARV 
users or ARV and ATM users. 
Table 1 : Patient characteristics, October 2014 (n=281) 
Patient 
Characteristic 
ARV users only 
(%) 
ARV and ATM 
users (%) 
Total [n (%)] 
Age 
18-25 96.3 3.7 27 (9.6) 
25-35 97.2 2.8 72 (25.6) 
30-35 98.1 1.9 53 (18.9) 
40-45 95.3 4.7 43 (15.3) 
45-50 92.3 7.7 52 (18.5) 
>50 88.2 11.8 34 (12.1) 
Gender 
Male 90.8 9.2 87 (30.1) 
Female 96.9 3.1 194 (69.9) 
Ethnic Group 
Black 94.9 5.1 272 (96.8) 
White 0 0 0 
Indian 100 0 3 (1.1) 
Coloured 100 0 6 (2.1) 
Other 0 0 0 
Level of Education 
No Education 94.2 5.8 69 (24.6) 





94.1 6.9 136 (48.4) 
Secondary 
Education 
96.5 3.5 57 (20.3) 
Tertiary 
Education 
100 0 19 (6.7) 
Place of Residence 
Urban 
Suburban 
98.3 1.7 58 (20.6) 
Urban 
Township 
95.6 4.4 181 (64.4) 
Peri-Urban 90 10 30 (10.7) 
Rural 83.3 16.7 12 (4.3) 
 
14 out of the 281 (4.98%) patients reported concurrent use of ATM with ARV during the study period 
Of the total patients surveyed. 65.8% reported ATM use before diagnosis with HIV whilst 77.6% 
reported previous ATM use after their HIV diagnosis (but before initiation with ARV). This is shown 
in Figure 2 ; 
 
Figure 2:  ATM use amongst PLWA 
None of the patients in the +ATM cohort had a tertiary qualification and all were of African ethnicity. 




ATM use before HIV diagnosis ATM use after HIV diagnosis but
prior to ARV initiation
Concurrent ATM and ARV use
ATM use amongst PLWA
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gender (p<0.001), age (p=0.032) education level (p<0.001) as well as place of residence (p=0.032). 
Multivariate analysis, obtained from combining all independent and controlling factors, for predicting 
ATM use resulted in education level (p<0.041), place of residence (p=0.004) and age (p<0.001). Further 
details are elucidated in Table 2.  
Table 2 : Statistical association of independent variables to predict ATM use 
Patient Characteristic % Concurrent ARV  




multivariate p value  
Age 
18-25 7.14  0.032 
  
 <0.001 






Male 57.14 <0.001 
 
 <0.018 
 Female 42.86 
Ethnic Group 
Black 100 <0.001  <0.001 
Level of Education 
No Education 28.57 <0.001 
 
 <0.041 
 Primary Education 57.14 
Secondary Education 14.29 
Place of Residence 
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Types of ATM  
The most commonly used ATM amongst the +ATM group was the African potato (H. hemerocallidea; 
used in its crude form or commercial preparations such as Inkomfe capsules or Moducare®) which was 
used by 9 patients (64.3%). This was followed by Sutherlandia at 21.4%. Two of the +ATM patients 
routinely used Stametta™ (a commercially prepared mixture of herbs including Aloe, aniseed oil and 
other nutrients which is sold Over-the-counter in pharmacies and health shops and is purported to 
‘strengthen the immune system and improve general well-being) and uBhejani (a traditional concoction 
of unknown composition sold in muthi markets in downtown Durban and townships). The average time 
for utilisation of ATM for the patients who took ARV and ATM concurrently was 4.3 months. In 
response to whether or not they had informed their medical doctor of their concurrent ATM use, all 14 
patients (100%) responded negatively and indicated that their doctors were not aware of their concurrent 
use of ATM.  
Reasons for ATM use 
77.5 (218/281) patients claimed to have previously or currently used ATM and cited one or more 
reasons for using ATM.  Reasons for using ATM included to boost immunity (68%), increasing appetite 
(61%), tonic for fatigue (55%), treating stomach pains/diarrhea (27%), alleviating fever (21%), treating 
joint pains (13%), treating headaches (11%), treating ARV side effects (7%) and elevating mood (4%). 
This is depicted in the table below 3;  
Table 3 : Utilisation of ATM (n=218) 
Indication Percentage (%) 
(n=218) 
Immune Supplementation 68 
Increasing Appetite 61 
Tonic 55 
Abdominal symptoms (Stomach pain/diarrhea) 23 
Fever 21 
Joint Pain 13 
Headache 11 
Treating ARV symptoms 7 
Elevating mood 4 
No particular reason 2 
91% (256/281) of the patients cited knowledge of the potential interactions between ATM and ARV 
and mentioned that the health care provider had underscored the potential dangers of simultaneous ARV 
and ATM use to them during pre-counselling before initiation of ART. 
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Clinical information  
Effect on CD4 
The majority (72%) indicated living with HIV for at least 3 years. As per the inclusion criteria, all 
patients surveyed were on the FDC drug, or its singular components (Tenofovir + Emtricibatine/3TC + 
Efavirenz) for a minimum period of 6 months. Based on the commencement of current ARV regimen, 
it was found that average period of use of the FDC combination drug at the time of first contact with 
the patients was 9.3 months. Information on previous ARV regimens was scanty and so was excluded 
from the study. The mean CD4+ values for the study period are represented in Table 4; 
Table 4 : CD4+ Cell counts (n=281) 









































The mean baseline CD4+ count in the –ATM cohort was 501 cells/mm3. There was a 9.2% increase in 
CD4+ counts in the –ATM group compared to the base line values after the 12 month prospective 
measurements subsequent to the 3.6% increase in CD4+ count at the 6-month interval. In comparison, 
the CD4+ counts in the +ATM cohort responded similarly to the –ATM group with incremental 
increases in mean CD4+ count of 6.0% and 9.5% at 6-month and 12-month interval respectively. The 
differences between the two means in the –ATM and +ATM groups at each CD4+ cell count measure 
were not significant at 5% level for Time 0 (p=0.18), Time 2 (p=0.26) and Time 3 (p=0.09). 
Effect on VL 
The mean viral loads (VL) for the patients during the study period are recorded in Table 5. 
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Table 5 : Viral Load (VL) measurements (n=281) 
 -ATM (n=267) +ATM (n=14) 




































-35.00% 9120 (±36.8) 
copies/mL. 
-21.9% 
At baseline, the VL in the -ATM group ranged from undetectable to 79120 copies/mL with an average 
of 12855 copies/mL. The +ATM group had a mean VL of 11677 copies/mL ranging from undetectable 
to 25435. The VL in the –ATM group reduced by 31.35% and 35% compared to the baseline VL in 
Time 2 and Time 3 respectively.   The differences between the two means in the –ATM and +ATM 
groups is significant at 5% level for Time 0 (p=0.013), marginally significant at Time 1 (p=0.048), 
Significant at Time 2 (p=0.040) and not significant at Time 3 (p=0.069). 
Discussion 
Overall, 65.8% (185/281) of the patients had used ATM before HIV diagnosis and 77.6% (218/281)   
after diagnosis. This indicated a health seeking approach by the respondents through their ATM 
practitioners after initial HIV diagnosis. These figures are in line with World Health Organization 
(WHO) estimates of about 80% worldwide ATM usage and even closer to a South African estimates of 
around 70% [5, 12].   
A majority of the patients surveyed (95.02%) did not use ATM concurrently with ARV. With the 
paucity of data on the concurrent use of ATM and ARV, and the fact that in-vitro studies indicate 
possible interactions between commonly used ATM and ARV [15], this finding can be viewed in a 
positive light. However, 4.98% (14/281) patients did report the concurrent use of ATM with ARV 
during the study period. The frequency of concurrent ATM use is comparable with similar studies in 
urban centres in Pretoria, South Africa [13] as well as Kano, Nigeria [8] which had 4.40% and 4.3% 
prevalence rate of concurrent ATM and ARV use respectively. This study differed vastly with a 2004 
Uganda study by Langlois-Klassen et al (2007), which reported a rate of 32.8% for concurrent ARV 
and ATM use [7]. The comparison of the results obtained in the current and other similar studies is 
compared using Table 6; 
     
22 
 
Table 8 : Comparison of ATM usage in PLWA 
The differences between the current study and the Kabarole could be attributed to different cultural and 
socio-economic factors. The current study was done in an urban metro in South Africa and the Kabarole 
study in a rural setting in Western Uganda. The researcher postulates that the lower rate of ATM usage 
could be due to better access to ART services, as is usually the case in an urban setting, and the fact that 
the Kabarole study was carried out in 2004 before the extensive ART roll-out programmes initiated by 
most governments. 
It is important to note that a 2008 study by Peltzer and Mnqundaniso in the same setting as the current 
study (urban eThekwini), found a prevalence rate of 44.4% for simultaneous ARV and ATM use [5].  It 
could be surmised that even greater access to ARV through universal access programs since 2008 and 
the reduced costs of these treatments would have resulted in a reduced demand for ATM [6]. 
Furthermore, there was growing evidence of in-vitro studies which indicated that commonly used South 
African ATM interacted with ARV [15, 16, 17]. 
Reduced ATM use in the current study may also be attributed to efforts by health care professionals in 
communication the potential for Herb-Drug interactions (HDI) to patients during pre-counselling 
sessions.  This study showed that 91% of the patients cited a knowledge of these potential HDI and that 
the health care provider had underscored the potential dangers of simultaneous ARV and ATM use to 
them during pre-counselling before initiation of ART. This is further reiterated by the vast differences 
in ATM use before HIV diagnosis, after HIV diagnosis and after initiation of ARV therapy (65.8%, 
77.6% and 4.98% respectively). 
The majority of the participants were relatively under-educated with only 6.7% having obtained a 
tertiary qualification and most (48.4%) only having a primary education. It was also found that the 
majority of the patients (64.4%) resided in an urban township. This unfortunately mirrors the 
epidemiology of HIV/AIDS in South Africa which largely affects the uneducated, females and persons 
of low income [4]. Multivariate analysis, obtained from combining all independent and controlling 
factors, for predicting ATM use showed that level of education (p<0.041), place of residence (p=0.004) 
and age (p<0.001) is associated with concomitant ARV and ATM use. 
The ATM used were African Potato, Sutherlandia, Stametta and unspecified traditional mixtures 
(including uBhejani). This showed a similar trend to the 2004, Pretoria study by Malangu which 
highlighted commonly used ATM as African Potato, Coconut as well as unspecified crude herbal 
mixtures [7]. 





















Period of study Current study 2008 2004-2005 2014 2004 
Setting Urban Urban Urban Urban Rural 
Concurrent ATM and 
ARV use 
4.98% 44.4% 4.40% 4.30% 32.80% 
ATM use after HIV 
diagnosis (before 
initiation of ARV)  
77.60% -  -  20.90% 63.50% 
ATM use before HIV 
diagnosis 
65.80% - - 27.50% 90.40% 
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Concomitant uses of ATM are generally discouraged during ARV treatment and so there is a chance of 
under reporting of the use of ATM use by the participants. This is expected in subjective measurements 
due to the perceived possibility of punitive consequences from the health-care-provider by the 
participant if he/she admits to the use of ATM.  This could also explain the finding that in all cases, 
patients who used ATM concurrently with ARV did not communicate their ATM use to their health 
care provider. This could also further indicate that patients are aware of the potential risks of 
concomitant use, but however, continue to do so in their attempt to self-medicate. 
Throughout the duration of the study, there was a steady increase in CD4+ counts in the cohort taking 
ARV alone as well as the cohort that used ATM and ARV concomitantly. Similarly, there was on 
average, a decline in VL in both cohorts, albeit, at different rates.  
The differences between the two VL means in the –ATM and +ATM groups are less than 0.05 and 
therefore are significant at 5% level for Time 0 (p=0.013), and marginally significant at Time 1 
(p=0.048) and significant at Time 2 (p=0.040). However, the differences in the VL means are not 
significant at Time 3 (p=0.069). As a result of the conflicting p values across the time lines, it can be 
concluded that the effect of ATM on ARV is inconclusive. 
Overall, statistical analysis found that in general, the effect of concomitant ARV and ATM use was not 
clinically significant. This was in concordance with a 2013 study by Gwaza et al on adult volunteers 
which showed that hypoxis is not associated with clinically significant changes in the pharmacokinetics 
of the ARV agent, LPV/r pharmacokinetics [18]. 
This study, however, differs from in-vitro studies by Mills et al., who in 2005 demonstrated the potential 
of hypoxis to increase metabolism of some drugs including ARV due to its significant effects on 
cytochrome P450 3A4 in-vitro metabolism [16].   Furthermore, a 2014 laboratory study also showed that 
H. hemerocallidea, E. purpurea, M. oleifera, T. officinale and L. frutescens inhibited major drug 
metabolising enzymes and had the potential to interact with ARV [17].   
Limitations 
The findings of this study may not be generalisable to PLWA in South Africa due to the fact that the 
study was concentrated in the eThekwini metro area. Several multi-centre studies in various centres 
(Urban, Per-urban, Rural) could shed more light on the actual prevalence rate of ATM use in PLWA as 
well as provide more reliable data on the effects of ATM on clinical outcomes of PLWA. Caution is 
therefore urged in generalising findings to other districts and provinces in the country.  
Clinical co-variates such as presence of opportunistic infections, changes in weight (BMI) of the 
patients and occurrence of Adverse Drug Reactions (ADR) as a result of ATM during the study period 
could not easily be retrieved from patient charts since the data in the patient charts was often disordered 
or absent. This information could possibly have added value to the study by demonstrating whether or 
not concomitant use of ATM and ARV may have resulted in increased occurrence of opportunistic 
infections, deterioration in weight of the participants or increased the prevalence of Adverse Drug 
Reactions in the +ATM cohort. 
Additionally, there is a need to explore and understand the knowledge, perceptions and attitudes of the 
health care workers and quantify their possible role, if any, in the continued reduction of prevalence 
rates of concurrent ATM and ARV use in PLWA. 
The limitations of this study could form the basis of future studies on this subject. 
Conclusion 
This study was able to establish the prevalence of ATM use in PLWA as well as other factors which 
impact on ATM use. This study was also able to show that there were no significant effects on the CD4+ 
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and inconclusive results on the VL of HIV infected patients in the eThekwini Metropolitan area who 
use ARV and ATM concurrently. This study was also able to establish the prevalence of ATM use in 
PLWA as well as other factors which impact on ATM use.  
Recommendations 
 The use of population pharmacokinetic approach in order to make the results more 
generalisable and to better establish a link between ARV plasma levels and concurrent ATM 
use on various patient characteristics. 
 The development of a pharmacodynamic model of the data in order to correlate patient 
characteristics, ARV plasma levels, ATM plasma levels with CD4+ and VL levels. 
 Continued vigilance by health care practitioners in counselling patients to not use ATM and 
ARV concomitantly. 
 The full professionalisation of THP and the incorporation of THP in the management of 
HIV/AIDS. 
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3.1.1 Phase 1 
Overall, 77.6% of the patients in this study had used ATM after HIV diagnosis and 65.8% before 
diagnosis. These figures are in line with WHO [4] and South African and Worldwide estimates of around 
70% and 80% respectively [6].  The majority of the patients surveyed (95.02%) did not use ATM 
concurrently with ARV. This was a welcome discovery as the effects of concurrent ARV and ATM use 
in humans are still largely uncertain despite the fact in-vitro studies indicate possible interactions 
between commonly used ATM and ARV [19].  
4.98% patients reported concurrent use of ATM with ARV during the study period. The frequency of 
concurrent ATM use is comparable with similar studies in urban centres in Pretoria, South Africa [17] as 
well as Kano, Nigeria [13] which had 4.40% and 4.3% prevalence rate of concurrent ATM and ARV use 
respectively. This study differed vastly with a 2004 Uganda study by Langlois-Klassen et al [12], which 
reported a rate of 32.8% for concurrent ARV and ATM use. The comparison is shown in Table 1; 








The vast differences between the current study and the Kabarole study could be attributed to different 
cultural and socio-economic factors. The current study was done in an urban metro in South Africa and 
the Kabarole study in a rural setting in Western Uganda. The researcher postulates that the lower rate 





















Period of study Current study 2008 2004-2005 2014 2004 
Setting Urban Urban Urban Urban Rural 
Concurrent ATM 
and ARV use 
4.98% 44.4% 4.40% 4.30% 32.80% 
ATM use after HIV 
diagnosis (before 
initiation of ARV)  
77.60% -  -  20.90% 63.50% 
ATM use before 
HIV diagnosis 
65.80% - - 27.50% 90.40% 
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of ATM usage in this study could be due to better access to ART services, as is usually the case in an 
urban setting, and perhaps the better knowledge of potential interactions between ARV and ATM by 
the patients surveyed. This however needs to be verified by further studies in this field. 
It is important to note that a study done in 2008 by Peltzer and Mnqundaniso [11] in the same setting as 
the current study (urban eThekwini), found a prevalence rate of 44.4% for simultaneous ARV and ATM 
use.  It could be surmised that increased access to ARV through universal access programs and the 
reduced costs of these treatments could have resulted in a reduced demand for ATM and account for 
the differences in ATM use between the 2008 and the current study [7]. Furthermore, it could be 
reasonably assumed that healthcare providers could have increased awareness and counselling to 
PLWA on the potential of dangers of concomitant ARV and ATM due to the fact that since 2005, there 
was growing body of evidence which suggested that commonly used South African ATM interacted 
with ARV in-vitro [22, 23]. 
 This claim was validated by the results of this study which showed that 91% of the patients cited a 
knowledge of these potential HDI and that the health care provider had underscored the potential 
dangers of simultaneous ARV and ATM use to them during pre-counselling before initiation of ART. 
This is further reiterated by the vast differences in ATM before HIV diagnosis, after HIV diagnosis and 
after initiation of ARV therapy (65.8%, 77.6% and 4.98%, respectively). 
There is a chance that the use of ATM use was under reported by the participants, as is expected in 
subjective measurements. This could be due to the belief of possible punitive consequences if the 
subject admits to the use of ATM whose concomitant use are largely discouraged in ARV treatment. 
The results must therefore be viewed with cautious optimism. 
The majority of the participants were relatively under-educated with only 6.7% having obtained a 
tertiary qualification.  Most of the participants (48.4%) only had a primary education. It was also found 
that the majority of the patients (64.4%) resided in an urban township. This unfortunately mirrors the 
epidemiology of HIV/AIDS in South Africa which largely affects the uneducated, females and persons 
of low income [4]. Multivariate analysis, obtained from combining all independent and controlling 
factors, for predicting ATM use showed that level of education level (p<0.041), place of residence 
(p=0.004) and age (p<0.001) is associated with concomitant ARV and ATM use. 
The ATM used where African Potato, Sutherlandia, StamettaTM and unspecified traditional mixtures 
(including uBhejani). This showed a similar trend to the 2004, Pretoria study by Malangu [17] which 
highlighted commonly used ATM as African Potato, Coconut as well as unspecified crude herbal 
mixtures.  
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3.1.2 Phase 2 
During the study period, there was a steady increase in CD4+ counts in the cohort taking ARV alone (-
ATM) as well as the cohort that used ATM and ARV concomitantly (+ATM). Similarly, there was on 
average, a decline in VL in both cohorts, albeit, at different rates.  
During the duration of the study, there was a steady increase in CD4+ counts in the cohort taking ARV 
alone as well as the cohort that used ATM and ARV concomitantly. Similarly, there was on average, a 
decline in VL in both cohorts, albeit, at different rates. The differences between the two VL means in 
the –ATM and +ATM groups are less than 0.05 and therefore not significant at 5% level for Time 0 
(p=0.013), and marginally significant at Time 1 (p=0.048) and significant at Time 2 (p=0.040). 
However, the differences in the VL means are non-significant at Time 3 (p=0.069). As a result of the 
conflicting p values across the time lines, it can be concluded that the effect of ATM on ARV is 
inconclusive. 
Statistical analysis using a standard t-test for independent means.  found that any effect of concomitant 
ARV and ATM use was not clinically significant. This was in concordance with a 2013 study by Gwaza 
et al study on adult volunteers in Zimbabwe which showed that hypoxis is not associated with clinically 
significant changes in the pharmacokinetics of the ARV agent, LPV/r pharmacokinetics [24]. 
A study carried out in 2004 by Mudzviti et al [26], found that there was evidence to suggest that some 
ATM used in Zimbabwe may increase incidence of certain types of adverse events when used in 
combination with antiretroviral drugs. This study was not able to ascertain such a phenomenon due to 
various factors including the lack of complete information on patient charts. 
3.2 CONCLUSION 
This study showed that there was no significant effects of concurrent ATM and ARV use on the clinical 
outcomes indicative of HIV disease progression (or ARV failure). The prevalence rate of concurrent 
ARV and ATM use was 4.98%; with the common ATMs used being H. hemerocallidea, uBhejani and 
Sutherlandia. The majority of the participants (91%) were aware of the possible interactions between 
ATM and ARV if taken concurrently. 
3.2.1 Limitations of the study 
Characteristics such as presence of Opportunistic infections (OI) and serial measurements of patient 
weight had been included in the initial study protocol. However, the researcher was not able to report 
on them due to the fact that several of the patient files did not have complete patient information. The 
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data in the patient charts was often disordered or absent or in some instances did not make sense. For 
example, a medicine to treat common opportunistic infections (e.g. cotrimoxazole tablets or 
clotrimazole cream) may have been included in the prescription within the patient charts, but the 
diagnosis (OI) not specified. Although it may have been reasonable in the above example to conclude 
the presence of pneumonia and fungal infections respectively, it was not always definitive whether the 
medicine was for prophylaxis or for treatment. In order to eliminate biases due to the above assumptions 
and lack of conclusive information, the researcher decided to exclude this information during the data 
analysis. 
Although a patient chart review was a convenient tool for the purposes of this study, several confounders 
could have been introduced. Possible confounders included the following; 
 ATM users did not use the same ATM. 
 The researcher was not assured by the participants that ATM use was consistent or intermittent. 
 The researcher was not assured of complete adherence to ARV by the participants. 
The study findings may not be generalisable to PLWA in the country in general due to the fact that the 
study was concentrated in four ART centres in the eThekwini metro (urban area). Several multi-centre 
studies in various centres (Urban, Per-urban, Rural) would result in data which is more generalisable to 
the South African population. Caution is therefore urged in generalising the findings of this study to 
other districts and provinces in the country. 
The limitations of this study could form the basis of future studies on this subject. 
3.3 RECOMMENDATIONS 
The following recommendations are made based on the results of the study: 
 Continued vigilance by health care practitioners in counselling patients not to use ATM and 
ARV concomitantly. 
 The use of a pharmacometric model on healthy human subjects in order to precisely determine 
the HDI. 
 The use of population pharmacokinetic approach in order to make the results more 
generalisable and to better establish a link between ARV plasma levels and concurrent ATM 
use on various patient characteristics. 
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 The development of a pharmacodynamic model of the data in order to correlate patient 
characteristics, ARV plasma levels, ATM plasma levels with CD4+ and VL levels. 
 Lastly, there is a need to explore and understand the knowledge, perceptions and attitudes of 
the OMP and quantify the possible role of OMP, if any, in the reduction of prevalence rates of 
concurrent ATM and ARV use in PLWA. 
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APPENDICES   





























Date of Commencement of  
Current ARV Regimen
3. CONCOMITANT TRADITIONAL MEDICINES  
ATM use before HIV diagnosisYES 185
NO 96
ATM use after HIV 
diagnosis (but not current) YES 218
NO 63
Do you currently take ARV 
and Tradition Medicines at 
the same time? YES 14
NO 267
How long have you been 
taking Traditional 
Medicines Concurrently? _______________
Is your Dr/Health 
Practitioner aware that you 
take TM YES 
NO 
Reason for Traditional 
Medicine Use 1.___________________
2.___________________






Are you aware of the 
potential interactions 
between TMs and ARV? YES 
No 
___________________
Date                                                        ___________________
Questionnaire Number                 ___________________
Associated Hospital Number      ___________________









Data Management Tool/Case Report Form - Phase 2
___________________
Associated Hospital Number ___________________
HIV DIAGNOSIS
Date of First Diagnosis ______________________
Date of first ARV ______________________ 
HIV Stage (According to WHO Staging) ______________________
1. ART Regimen 1.___________________
2.___________________
3.___________________
Date of Commencement of  Current Regimen
2. Previous ART Regimen/s 1.___________________
2.___________________
3.___________________
3. CONCOMITANT DISEASE/Adverse Event (Opportunistic infection)






4. CLINICAL TESTS Prospective Data
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My name is Mncengeli Sibanda, a postgraduate student in the department of Pharmaceutical Sciences, 
UKZN Westville Campus. 
You are being invited to consider participating in a study that involves research on the effects of 
concurrent use of ARV and African Traditional medicines on the CD4, VL and weight of HIV infected 
patients in KZN. 
The aim and purpose of this research is to study the effects of African traditional medicines on 
Antiretroviral drug efficiency The study is expected to enrol 200 participants in the Ethekwini 
Metropolitan Area. It will involve me visiting the ARV Clinic looking at your file and prescription chart 
to determine the effects of traditional medicines on your HIV outcome. If necessary, I will discuss your 
treatment options with your doctor. The duration of your participation if you choose to enrol and remain 
in the study is expected to be approximately 6 months.  
We hope that the study will create the awareness amongst HIV infected persons on the possible effects 
of using TMs together with ARV on their overall health.  
This study has been ethically reviewed and approved by the UKZN Biomedical research Ethics 
Committee (BREC REF: BE 727/14). 
In the event of any problems or concerns/questions you may contact the researcher at 0725877246 or 
the UKZN Biomedical Research Ethics Committee, contact details as follows:  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban 4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
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Or contact my Supervisors; 
Dr Panjasaram Naidoo (supervisor), Cell: 0839645429; email: naidoopj@ukzn.ac.za Manimbulu 
Nlooto (Co-supervisor), Cell: 0828450224; email: Nlooto@ukzn.ac.za 
Participation in this research is completely voluntary and you may withdraw from participating in the 
study at any point. In the event of refusal/withdrawal of participation you will not incur penalty or loss 
of treatment or other benefit to which you are normally entitled.  
Confidentiality is paramount in this study and to protect your identity, a unique study number will be 
assigned to you which will ensure privacy of your information as the results cannot be directly linked 
to you. Only the study number will be used as a reference in the database to protect your identity. The 
reporting on patients from this study will be done anonymously. Your name and identity numbers are 
not included on all questionnaires and data collection forms. All questionnaires and data extraction 
forms will be coded and no one else except us will have access to your information. Questionnaires and 
all other instruments used to collect information will be destroyed after five years by shredding after 
the study is complete. Equally information stored on computers will be protected by a password and 
will be deleted five years after the study is complete. 
Information collected during and after the study will be stored in a locked cupboard for 5 years in the 
supervisor’s office. Thereafter it will be destroyed by shredding. 
 Patients taking part in the study will not receive direct feedback on their CD4 levels unless it is 
indicative of non-compliance to ART or treatment failure in which case the responsible clinician will 
be contacted. 
You will not personally incur any costs as a result of participation in the study. Participation is voluntary 
hence you will not receive any reimbursement for participation. There is no financial remuneration for 
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Appendix 3b:    Study information Leaflet (Zulu) 
 
  “Isifundo sokuhlola kokusetshenziswa kwemithi yesintu ndawonye namaphilisi okuthithibalisaisifo se 
ngculazi (ARV) kubantu abaphetwe yisifosengculazi eKZN” 
Mnumzane/Nkosikazi, 
Ngingusokhemisi oyenzaizifundoze Masters enyuvesiyase UKZN. Ngiyenza ucwaningo mayelana 
kokusetshenziswa kwemithi yesintu ndawonye namaphilisi okuthithibalisaisifo se ngculazi. 
Ngithanda ukumema ukuthi ubeyinenyeyalo ucwaningo. Ngicela ufunde iminingwanoyalo cwaningo. 
Uma unemibuzo, ukhululekile ukubuza nomanini, uzothola incazelo ngaphambi kokuthi ukhethe 
ukubayinxenye yalocwaningo nomaqha. 
Locwaningo luzokwenziwa kubobonke abantu abagulayo abaphuza umshanguzowengculazi. 
Ngizobuka ifayela lakho nemithi obhalelwe yona ngudokotela ukubona ukuthingabe uhlangabeza 
nanazo izimpawu ezingalindele kanga ezingenziwa ukuphuza umshanguzo. Uma kunesidingo, 
ngizoxoxisana nodokotela ngemishanguzo yakho. 
Imvumo yokwenza locwaningo ngiyithole enyuvesiyase UKZN esikhungwenisase MEDICAL SCH, 
sekomidi elingu nyazilonke ucwaningo olwenziwa ngabafundi, kanye nemvumo evelakumphathi 
omkhulu wesibhedlela saseUKZN. Igama lakho alizukubhwalwa ndawonakokonke okuqondenenawe 
kuzogcinwa kuyimfihlo. 
Awuphoqelekile ukubayinxenye yalocwaningo. Uma uvumaukuba yinxenye, uvumelekile ukuyeka 
ukubayinenye yalocwaningo lungakapheli ngaphandle kokujeziswa. Uma uvuma ukubayinxenye 
yalocwaningo. Kuzodingeka ukuthi ubhale ephenile sivumelwano salo cwaningo imininingwane yakho 
enjengegama lakhonesibongo, beseuyasayina. 
Ukuba yinxenye kwakho kulolocwaningo kuzoba yintokozo enkulu kithi. Uma ufuna ukucaciseleka 
nganoma ikuphi okuthinta ucwaningo, sicela ukhululeke ukubuza lowo ozobe exoxisana nawe / 
ekubuza imibuzo kumbe uthinthe; 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  





KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za 
Kumbe uthinte abakhokheli bami; 
Dr Panjasaram Naidoo (supervisor), Cell: 0839645429; email: naidoopj@ukzn.ac.za Manimbulu 
Nlooto (Co-supervisor), Cell: 0828450224; email: Nlooto@ukzn.ac.za 
Yimiozithobayo, 
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Appendix 4a:    Informed Consent Form (English) 
I _____________ have been informed about the study entitled “AN INVESTIGATION INTO THE 
EFFECTS OF CONCURRENT USE OF ARV AND AFRICAN TRADITIONAL MEDICINES ON 
THE CD4, VL AND WEIGHT OF HIV POSITIVE PATIENTS IN KZN” by Mr. Mncengeli Sibanda. 
I understand the purpose and procedures of the study. 
I have been given an opportunity to answer questions about the study and have had answers to my 
satisfaction. 
I declare that my participation in this study is entirely voluntary and that I may withdraw at any time 
without affecting any treatment or care that I would usually be entitled to. 
I have been informed about any available compensation or medical treatment if injury occurs to me as 
a result of study-related procedures. 
If I have any further questions/concerns or queries related to the study, I understand that I may contact 
the researcher on 0725877246. 
If I have any questions or concerns about my rights as a study participant, or if I am concerned about 
an aspect of the study or the researchers then I may contact: 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
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Or contact my Supervisors; 
Dr Panjasaram Naidoo (supervisor), Cell: 0839645429; email: naidoopj@ukzn.ac.za Manimbulu 
Nlooto (Co-supervisor), Cell: 0828450224; email: Nlooto@ukzn.ac.za 
 
 
____________________      ____________________ 
Signature of Participant                            Date 
 
 
____________________   _____________________ 
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Appendix 4b:    Informed Consent Form (Zulu) 
Isitatimende esimaqondana ngokuhlanganyela ohlolweni lokwelashwa 
kuPhrojekthi/Yocwaningo 
Igamale Phrojekthi/loCwaningo/lohlolo; 
“Isifundo sokuhlola kokusetshenziswa kwemithi yesintu ndawonye namaphilisi okuthithibalisa isifo se 
ngculazi (ARV) kubantu abaphetwe yisifosengculazi eKZN” 
Ngilufundile ulwazi/ngizizwile izinhloso nezinjongo zocwaningo oluhlongoziwe futhi nganikezwa 
nethuba lokubuza imibuzo nganikezwa nesikhathi esanele sokuphinde gicabange. 
Ngiyazi ukuthi loluphenyo lungani futhi ngiyavuma ukubawomunye abangenele loluphenyo. Imvume 
yami incikeko kulandelayo imiphume lange keize imuveze umnikazi. Imiphumela ingasetshenziswa 
nomaishicile lweukuze abasiza ngokunakekelwa kwabantu abalesifo sengculazi. 
Uma ufuna ukucaciseleka nganoma ikuphi okuthinta ucwaningo, sicela ukhululeke ukubuza lowo ozobe 
exoxisana nawe / ekubuza imibuzo kumbe uthinthe; 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 




Loba abakhokheli bami; 
Dr Panjasaram Naidoo (supervisor), Cell: 0839645429; email: naidoopj@ukzn.ac.za Manimbulu 
Nlooto (Co-supervisor), Cell: 0828450224; email: Nlooto@ukzn.ac.za 
Ngingathokoza kakhulu umaungasayina ifomu lokungivumela ukubangiqhubeke nophenyo. 
Ngiyabongakakhulu. 
____________________      ____________________ 
Igama (ngamagama amakhulu)         Sayina 
 
 
____________________   _____________________ 
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Appendix 5:    Request for permission from DOH/CEO of Hospital 
The Chief Executive Officer, 
“X” Hospital 
Dear Sir/Madam, 
My name is Mncengeli Sibanda; I am an M Pharm student in the Discipline of Pharmaceutical Sciences, 
College of Health science, University of KwaZulu-Natal, (Westville Campus). I am required to carry 
out a dissertation in fulfilment of the requirements of my studies. The title of which is “AN 
INVESTIGATION INTO THE EFFECTS OF CONCURRENT USE OF ARV AND AFRICAN 
TRADITIONAL MEDICINES ON THE CD4, VL AND WEIGHT OF HIV POSITIVE PATIENTS IN 
KZN” 
I kindly request permission to conduct the study at your hospital and request access to Out-patients and 
their records in the ARV clinic. 
Attached, please find a copy of the protocol as well as SREC and MREC approval. 
You may also contact my supervisors: Dr Panjasaram Naidoo (supervisor), Cell: 0839645429; email: 
naidoopj@ukzn.ac.za Manimbulu Nlooto (Co-supervisor), Cell: 0828450224; email: 
Nlooto@ukzn.ac.za, at UKZN, Discipline of Pharmaceutical Sciences, Westville Campus for more 
information. 




Mncengeli Sibanda M. Pharm Student (Cell: 0725877246) 
CC:  Dr Panjasaram Naidoo, Supervisor (Cell: 0839645429) 
           Manimbulu Nlooto, Co-Supervisor (Cell: 0828450224) 
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Appendix 9:     Certificate in Good Clinical Practices 
 
 
